For the hepatitis B session, I found it particularly interesting. Many presentations discussed factors associated with HBsAg seroclearance. Some important factors included stopping treatment and whether retreatment after stopping could im...
Recent Application of AASLD Practice Guidelines and US Algorithm for Treatment of Chronic Hepatitis B: 346Kapkov, Denis V.Meyer, Trinh B.Meyer, DouglasClain, David J.Bodenheimer, Henry C. JrMin, Albert D.Official journal of the American College of Gastroenterology | ACG...
Hepatology Digest:In conjunction with this study, could you please outline the predictive value of HBV RNA and HBcrAg in the treatment of different populations with chronic hepatitis B? Dr Zoulim:Since these biomarkers are v...
New data on defining HCC riskhave emerged for hepatitis B virus,1,2hepatitis C vi-rus,3andautoimmunehepatitis.4deemed cost-effective if the expected HCC risk exceeds1.5% per year in patients with hepatitis C and 0.2%per year in patients with hepatitis B. Analysis of recentstudies show that ...